Drug Type Monoclonal antibody |
Synonyms NI-0401, NI-0401/α-CD3, TZLS-401 |
Target |
Mechanism CD3ε inhibitors(CD3e molecule inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Secondary Progressive | Phase 2 | US | 15 Nov 2023 | |
Multiple Sclerosis | Phase 2 | GB | 27 Apr 2023 | |
COVID-19 | Phase 2 | - | 30 Apr 2022 | |
COVID-19 respiratory infection | Phase 2 | - | 30 Apr 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | - | 01 Dec 2017 | |
Nonalcoholic Steatohepatitis | Phase 2 | - | 01 Dec 2017 | |
Acute cellular graft rejection | Phase 2 | FR | 01 Aug 2007 | |
Acute rejection of renal transplant | Phase 2 | FR | 01 Aug 2007 | |
Crohn Disease | Phase 2 | NL | 13 Jun 2006 | |
Diabetes Mellitus, Type 1 | Phase 2 | EU | - |
GlobeNewswire Manual | Not Applicable | 6 | oazyedeugt(gnwmuafbhd) = swiuxalapn jbzkrfbgsh (vcnxwzgeww ) View more | Positive | 25 Apr 2024 | ||
GlobeNewswire Manual | Phase 2 | 10 | bqjrdadszn(xkuzygrxuo) = six out of eight Intermediate Size Patient Population Expanded Access (EA) patients have shown improvements in fatigue scores. PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. ywjbdkgkvv (tpvpzggzbw ) | Positive | 08 Jan 2024 | ||
Phase 1 | 2 | tkffogcbbv(dsijmqisrt) = The patient showed clinically significant improvement on the Extended Disability Status Scale (EDSS) gdtbshtvze (aeombnsuoh ) | Positive | 20 Sep 2022 |